

Peripheral Venous Catheter Infection - Microbiology Summary Clinical Guideline

Reference number: CG-ANTI/4006/22

Management: peripheral venous catheter localised infection without sepsis

Clinical concerns re peripheral venous catheter localised infection (e.g. pain, erythema, warmth, tenderness, and/or swelling of the skin) without sepsis

Treatment: remove the peripheral venous catheter

Investigate

- Blood sciences:
 - FBC, CRP, lactate, U&E, and LFT
- Microbiology:
 - ± Tip for culture and susceptibilities: for example, if clinical concerns re bloodstream infection, sepsis, or septic shock
 - ± Pus/Wound swab: e.g. if purulent discharge
 - ± Blood cultures. Indications for initial blood cultures include the initiation of treatment with intravenous antibiotics

Treatment: empiric, per oral antibiotics

- First line: flucloxacillin 1 g 6 hourly
- Second line: clarithromycin 500 mg 12 hourly
- Third line: doxycycline 100 mg 12 hourly
- Fourth line: clindamycin 300-450 mg 6 hourly
- Fifth line: linezolid 600 mg 12 hourly

or*

Treatment: empiric, intravenous antibiotics*

- First line: flucloxacillin 2 g 6 hourly
- Second line, if penicillin allergy and/or clinical concerns re the risk of MRSA: glycopeptide (vancomycin or teicoplanin), [dose as per hospital guidelines](#), vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 15-30 mg/l
- Third line, if penicillin allergy: clindamycin 600 mg 6 hourly
- Fourth line, if penicillin allergy and/or clinical concerns re the risk of MRSA: linezolid 600 mg 12 hourly (NB or per oral [absorption 100%])
- Fifth line, if penicillin allergy and/or clinical concerns re risk MRSA: daptomycin 4-6 mg/kg daily

Directed antibiotics with microbiology cultures and susceptibilities
Duration of antibiotics 5-7 days

* Indications for empiric, intravenous antibiotics include: (1) progression of symptoms and signs after 48 hours of per oral antibiotics; (2) suboptimal vasculature - e.g. chronic venous insufficiency, diabetes mellitus, peripheral vascular disease - impeding delivery of antibiotics; (3) intolerant of per oral antibiotics

Management: peripheral venous catheter infection with sepsis

Clinical concerns re peripheral venous catheter infection (e.g. pain, erythema, warmth, tenderness, and/or swelling of the skin)

and

Clinical concerns re sepsis (life threatening organ dysfunction caused by a dysregulated host immune response to infection) or septic shock

Treatment: remove the peripheral venous catheter

Investigate

- Blood sciences:
 - FBC, CRP, lactate, U&E, and LFT
- Microbiology:
 - Blood cultures
 - ± Tip for culture and susceptibilities: for example, if clinical concerns re bloodstream infection, sepsis, or septic shock
 - ± Pus/Wound swab: e.g. if purulent discharge

If for empiric, intravenous antibiotics, ensure completion of the Sepsis 6

Treatment: empiric, intravenous antibiotics

- First line: glycopeptide (vancomycin or teicoplanin), [deep-seated dosage as per hospital guidelines](#), vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l; **and** piperacillin tazobactam 4.5 g 6 hourly
- Second line, [if non-immediate without systemic involvement penicillin allergy](#): glycopeptide (vancomycin or teicoplanin), [deep-seated dosage as per hospital guidelines](#), vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l; **and** ceftazidime 2 g 8 hourly
- Third line, [if immediate rapidly evolving or non-immediate with systemic involvement penicillin allergy](#): glycopeptide (vancomycin or teicoplanin), [deep-seated dosage as per hospital guidelines](#), vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l; **and** ciprofloxacin 400 mg 8 hourly

Blood cultures positive

Antibiotics intravenously ± per oral

Please note relevant hospital guidelines on [Staphylococcus aureus bloodstream infection](#), [blood cultures and bloodstream infections](#), and [native and prosthetic valve infective endocarditis](#)

Blood cultures negative 48-72 hours

Stop antibiotics intravenously

Directed, per oral antibiotics with microbiology cultures and susceptibilities
Total duration of antibiotics 5-7 days

or

Empiric, per oral antibiotics (flucloxacillin or clarithromycin or doxycycline, etc.)
Total duration of antibiotics 5-7 days

References

- Bennett, J. E., Dolin, R., and Blaser, M. J.** 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease, 8th Edition. Elsevier.
- Calderwood, M. S.** 2019. Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis. UpToDate. Available at: [Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis - UpToDate](#) (accessed May 2020).
- Calderwood, M. S.** 2019. Intravascular non-hemodialysis catheter-related infection: Treatment. UpToDate. Available at: [Intravascular non-hemodialysis catheter-related infection: Treatment - UpToDate](#) (accessed May 2020).
- CREST.** 2005. Guidelines on the management of cellulitis in adults. Available at: <http://www.acutemed.co.uk/docs/Cellulitis%20guidelines,%20CREST,%2005.pdf> (accessed July 2019).
- Gaynes, R. and Jacob, J. T.** 2020. Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology. UpToDate. Available at: [Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology - UpToDate](#) (accessed November 2020).
- Mermel, L. A.** 2017. Short-term Peripheral Venous Catheter-Related Bloodstream Infections: A Systematic Review. Clinical Infectious Diseases.
- National Institute for Health and Care Excellence (NICE).** 2019. Cellulitis and erysipelas: antimicrobial prescribing (Draft for consultation, April 2019). Available at: www.nice.org.uk (accessed May 2019).
- Ripa, M., Morata, L., Rodriguez-Nunez, O., Cardozo, C., Puerta-Alcade, P., Hernandez-Meneses, M., Ambrosioni, J., Linares, L., Bodro, M., Valcarcel, A., Casals, C., de los Angeles Guerrero-Leon, M., Almela, M., Garcia-Vadal, C., del Rio, A., Marco, F., Mensa, J., Martinez, J. A., and Soriano, A.** 2018. Short-Term Peripheral Venous Catheter-Related Bloodstream Infections: Evidence for Increasing Prevalence of Gram-Negative Microorganisms from a 25-Year Prospective Observational Study. Antimicrobial Agents and Chemotherapy.
- Smith, R. N. and Nolan, J. P.** 2013. Central venous catheters. BMJ.
- Spelman, D.** 2019. Cellulitis and skin abscess: Clinical manifestations and diagnosis. Available at: https://www.uptodate.com/contents/cellulitis-and-skin-abscess-clinical-manifestations-and-diagnosis?topicRef=110530&source=see_link (accessed May 2019).
- Spelman, D.** 2019. Cellulitis and skin abscess in adults: Treatment. Available at: <https://www.uptodate.com/contents/cellulitis-and-skin-abscess-in-adults-treatment> (accessed May 2019).
- Sullivan, T. and de Barra, E.** 2018. Diagnosis and management of cellulitis. Clinical Medicine.
- Weng, Q. Y., Raff, A. B., and Cohen, J. M.** 2017. Costs and Consequences Associated With Misdiagnosed Lower Extremity Cellulitis. The Journal of the American Medical Association Dermatology.

Document control

Development of guidelines:	Angelina Dyche, Kayleigh Lehal, Dr Peter Slovak
Consultation with:	Antimicrobial Pharmacist, Lead Antimicrobial Pharmacist, Microbiology Consultant
Version:	1
Approval date:	AMSG – 08/03/2022, CDGS – 22/03/2022, Surgery – April 2022, Medicine - Pending
Changes from previous version:	Introduction, Investigation, Treatment, Management, References, Document control
Date uploaded:	14/7/2022
Next review date:	pending
Key contacts:	Dr Peter Slovak, Microbiology Consultant p.slovak@nhs.net Kayleigh Lehal, Lead Antimicrobial Pharmacist kayleigh.lehal@nhs.net Angelina Dyche, Antimicrobial Pharmacist angelinadyche@nhs.net